Half the people I know who lift heavy, or whose gut has never quite behaved, have said the same three letters to me this year: BPC. As in BPC-157, a fifteen-amino-acid peptide that is native to human gastric juice, which is to say your own gut already makes something very like it. People inject it into a bad shoulder or an inflamed gut and swear it brings them back. It is cheap, it comes from a compounding pharmacy, and no drug company has a blockbuster riding on it. So I paid close attention when a group with the drug industry’s fingerprints on it started working to make sure you can’t get it.

The Partnership for Safe Medicines has filed comments urging the FDA’s Pharmacy Compounding Advisory Committee, which meets July 23 and 24, to keep seven peptides off the list of substances pharmacies are allowed to compound: BPC-157, KPV, TB-500, MOTS-c, Emideltide (better known as DSIP), Semax, and Epitalon. Allowing these, the group warns, would “effectively transform the American public into involuntary clinical trial participants.” It sounds like patient protection. Then you look at who is doing the protecting.

The Partnership for Safe Medicines is not a grassroots patient coalition. A KFF Health News analysis of tax disclosures found that more than a third of the groups in the partnership had received funding from PhRMA, the drug industry’s main lobby, which is itself a dues-paying member. Its longtime executive director, Scott LaGanga, ran the nonprofit for a decade while holding a senior job at PhRMA, and NPR reported the same ties back when the group was spending to fight cheaper drug imports from Canada. This is the outfit now telling the FDA which peptides you may and may not have.

Let me tell you what these molecules actually do, because the “unproven and dangerous” framing skips the biology that got me curious.

Take BPC-157. In animal studies it does something genuinely odd with nitric oxide, the body’s own signal for widening blood vessels and settling inflamed tissue: it seems to push the system back toward balance whether the animal has too little NO or too much, and it switches on the VEGF receptor pathway that sprouts new blood vessels into a wound. Wait, why would a gut peptide grow blood vessels in a torn tendon? Because healing is healing. The repair machinery your intestinal lining uses to patch itself is close to what a ligament needs, and BPC-157 appears to sit on the switch that turns it on. MOTS-c is stranger. It is encoded not in your nuclear DNA but inside the mitochondria, the little power plants in every cell, and it travels to the nucleus to retune how you burn fuel, which is why the longevity crowd cares about it. Epitalon, studied for years by Vladimir Khavinson’s group in Russia, rides on the claim that it nudges telomerase, the enzyme that maintains the caps on your chromosomes.

Here is the catch, and this publication does not shill: almost all of that evidence is preclinical. Rats, cell cultures, small human series. There is no large randomized trial showing BPC-157 fixes your gut or MOTS-c extends your life, and anyone selling you certainty is selling you something. The human data is thin.

Now watch what gets built on top of that thin data. The FDA has flagged these seven as too risky to compound and routed them to its advisory committee, whose staff is leaning toward keeping them off the approved list for good. The Partnership for Safe Medicines showed up to cheer that on. And the honest question the safety language is designed to keep you from asking is: who benefits when a peptide your neighborhood pharmacy makes for a few dollars gets declared off-limits?

Not the pharmacy. Follow the money to the agency doing the declaring. Industry user fees have climbed from about 20 percent of the FDA’s budget in 2007 to roughly 49 percent in 2025, and in the prescription-drug review program specifically, that industry money now covers 77 percent of the costs. The regulator deciding whether you can access a cheap, off-patent molecule is funded, nearly to the half, by the companies that sell the expensive on-patent ones. None of these seven peptides can be patented the way a novel drug can, because they are natural sequences, so no company can build a franchise on them. Push them out of compounding and into the formal approval pipeline, and the only players who can afford the trials are the same firms writing the FDA’s checks. The “involuntary clinical trial” line lands differently once you see that the alternative on offer is: wait for a drug company to run the trial, then buy the result back at brand prices.

If the move feels familiar, it should. It is the one the Partnership for Safe Medicines just ran on GLP-1s, which is my beat, so I watched it up close. When compounded semaglutide and tirzepatide flooded the market during the shortage, the group applauded the FDA for shutting compounding down and declared “the end of GLP-1 compounding.” And some of those GLP-1 safety worries were legitimate. There were real dosing errors, real contaminated vials, and the BMJ raised fair questions about copycat weight-loss drugs. The problem was never that the safety issues were invented. It is that this group turns up loudest precisely when a cheap, off-patent competitor threatens a branded blockbuster, and stays much quieter when the branded product is the one hurting people. A watchdog that barks at the pharmacy and rarely at the manufacturer is not a watchdog. It is a fence.

So this is my conclusion. I am not injecting Epitalon on a Russian telomere theory, and I would want a real human trial before I trusted BPC-157 with anything serious. But I will not hand the decision about which off-patent molecules I can reach to a nonprofit wearing PhRMA’s fingerprints, and from now on I am going to read the word “safety” very slowly every time this particular group says it out loud.

Sources

  1. Partnership for Safe Medicines – comments urging the FDA PCAC to reject seven compounded peptides (July 2026)
  2. FDA – July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
  3. KFF Health News – Nonprofit Linked to PhRMA Rolls Out Campaign to Block Drug Imports
  4. NPR – Nonprofit Working to Block Drug Imports Has Ties to Pharma Lobby
  5. Congressional Research Service – The FDA Budget: Fact Sheet (user-fee share of FDA funding)
  6. NCBI Bookshelf – FDA User Fees: Examining Changes in Medical Product Development (PDUFA cost share)
  7. NCBI PMC – BPC-157, gastric pentadecapeptide: nitric oxide and VEGF mechanism (preclinical)
  8. NCBI PMC – MOTS-c, the mitochondrial-derived peptide
  9. Partnership for Safe Medicines – Applauds FDA Action to Curb Compounded GLP-1 Medications (2026)
  10. BMJ – Are “copycat” compounded weight loss drugs safe? (2025)